Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer
Journal of Oncology Pharmacy Practice · 08.07.2026
DOI: 10.1177/10781552261469836 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 08.07.2026. Verfasst von Tala Al-Bdour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, King Hussein Cancer Center, Al-Jubeiha, Amman, Jordan. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
Taxane-induced peripheral neuropathy (TIPN) is a debilitating side effect of taxane chemotherapy. However, real-world studies on TIPN requiring treatment are limited. This study evaluated the incidence, characteristics, and outcomes of TIPN requiring treatment in patients with breast cancer.
Methods
A retrospective study was conducted at King Hussein Cancer Center and included adult patients with breast cancer treated with taxane-based chemotherapy regimens from January 2023 to August 2025. Patients who developed TIPN requiring pain medications were identified. Baseline characteristics, taxane related data, onset of TIPN requiring treatment, clinical outcomes, and pain management strategies were assessed using descriptive analysis.
Results
Among 1353 patients, 201 (15.0%) developed TIPN requiring treatment. The mean age was 54 years (SD ± 10.5). Among these patients, 135 (67.2%) received docetaxel and 66 (32.8%) received paclitaxel. Early-stage breast cancer was reported in 133 (66.0%) patients, while 68 (34.0%) had metastatic disease. TIPN requiring treatment occurred most frequently after the third cycle with docetaxel ( n = 104, 77.0%), and after the fifth cycle with paclitaxel ( n = 30, 45.5%). TIPN requiring treatment resulted in emergency department visits in 16 (8.0%) patients, chemotherapy dose reductions in 63 (31.3%), treatment discontinuation in 23 (11.4%), and cycle delays in 3 (1.5%) patients. Initial pharmacologic management consisted of gabapentin monotherapy (80.0%), duloxetine monotherapy (10.5%), and combination of gabapentin and duloxetine (7.0%).
Conclusions
During the study period, TIPN requiring treatment affected one- in- seven patients with breast cancer and resulted in significant treatment modifications, highlighting opportunities for proactive management strategies to improve patient care and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, King Hussein Cancer Center, Al-Jubeiha, Amman, Jordan.
ORCID-Profile: Tala Al-Bdour, Nour Faqeer
Zitieren
APA
Al-Bdour, T., Abualoush, Z., Alshwayat, W., & Faqeer, N. (2026). Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552261469836
Vancouver
Al-Bdour T, Abualoush Z, Alshwayat W, Faqeer N. Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer. Journal of Oncology Pharmacy Practice. 2026. doi:10.1177/10781552261469836
BibTeX
@article{AlBdour2026,
author = {Al-Bdour, Tala and Abualoush, Zahieh and Alshwayat, Wala'a and Faqeer, Nour},
title = {Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer},
journal = {Journal of Oncology Pharmacy Practice},
year = {2026},
doi = {10.1177/10781552261469836}
}
EUVIMED